rawfin.tv
Merck Reports Positive Phase 2b Results for Skin Therapy
MarketsstocksAI Generated

Merck Reports Positive Phase 2b Results for Skin Therapy

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

Merck & Co. announced positive initial results from its Phase 2b MK-7240-012 trial for tulisokibart, an investigational skin therapy. The promising data suggests potential for the new treatment in the dermatology market.

MerckClinical TrialsSkin TherapyPharmaceuticals

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks